BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Kucera Pharmaceutical Announces Discovery Of A Novel Antiviral Compound For The Potential Treatment Of Severe Acute Respiratory Syndrome (SARS)


10/19/2005 5:10:17 PM

WINSTON-SALEM, N.C., March 4 /PRNewswire/ -- The Kucera Pharmaceutical Co. announced today it has within its armamentarium a novel antiviral compound that has confirmed activity against the causative viral agent responsible for SARS. Patents on this use and other antiviral applications were recently filed.

"The preliminary data obtained through independent laboratory testing are encouraging and support the continued development of this novel antiviral compound," said Dr. Ronald A. Fleming, the company's Chief Scientific Officer.

"This company has a large inventory of powerful antiviral and anticancer agents," said Russ H. Read, CEO. "We are steadily moving forward the candidate drugs discovered within our platform so they can be licensed out for final development and commercialization."

Kucera Pharmaceutical Co., an award-winning North Carolina-based biotechnology company ( http://www.kucerapharma.com/ ), is a 2001 spin-off of Wake Forest University Health Sciences and the University of North Carolina at Chapel Hill. It has in development patented novel antiviral and anti-cancer agents.

Kucera is headquartered at the Piedmont Triad Research Park ( http://www.ptrp.org/ ) in downtown Winston-Salem and has laboratories in Durham, N.C.

CONTACT: Russ H. Read, CEO Kucera Pharmaceutical Co. (336) 723-7133 Dr. Ronald A. Fleming Chief Scientific Officer Kucera Pharmaceutical Co. (336) 403-6819

Kucera Pharmaceutical Co.

CONTACT: Russ H. Read, CEO, +1-336 723-7133, or Dr. Ronald A. Fleming,Chief Scientific Officer, +1-336-403-6819, both of Kucera Pharmaceutical Co.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES